DNA X, Inc. SONM
3.92
(0.03)
(0.76%)
as of 25 Sep
- Market cap
- $5.9M
- P/E
- 0.0×
Follow SONM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 0.18 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (1.52) | |
P/B ratio |
— | — | — | 0.00 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | 0.15 | |
EV/EBITDA |
— | — | — | 0.18 | |
EV/Operating CF |
— | — | — | (0.34) | |
EV/FCF |
— | — | — | (0.34) | |
Quick Ratio |
0.42 | 0.62 | 0.03 | 0.40 | |
Current Ratio |
0.57 | 0.76 | 0.57 | 0.78 | |
Net Debt/EBITDA |
0.76 | 0.33 | (0.07) | 0.62 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.62% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | (0.36) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 1.32 | |
Operating CF/Net income |
1.60 | (0.55) | 0.23 | 1.48 | |
Capex/Depreciation |
(1.03) | 78.09 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 1.12% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 34.63% | |
Intangible Assets out of Total Assets |
0.31 | 0.00 | 0.00 | 0.23 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 1.02% | |
Graham Net Nets |
— | — | — | (0.99) | |
Graham Number |
— | — | — | 39.91 | |
Earnings Yield |
— | — | — | (915.10%) | |
Free Cash Flow Yield |
— | — | — | (245.15%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 16.46 | |
Operating CF per Share |
(1.48) | (2.74) | (2.77) | (7.14) | |
Capex per Share |
(0.07) | 2.65 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.55) | (0.09) | (2.77) | (7.14) | |
Cash per Share |
0.67 | 0.94 | 1.80 | 2.17 | |
Shareholders Equity per Share |
(0.91) | (0.78) | (11.01) | (0.71) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.91) | (0.78) | (11.01) | (0.71) | |
Free Cash Flow |
(2.09) | (0.11) | (2.00) | (7.03) | |
Working Capital |
(2.23) | (1.02) | (21.72) | (8.55) | |
Capital Expenditures |
(0.09) | 3.36 | — | — | |
Net Current Asset Value |
(2.83) | (2.52) | (22.94) | (10.62) | |
EV/EBIT |
— | — | — | 4.20 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (29.31%) | |
Price to Operating Income |
— | — | — | 0.24 | |
| Other line items | |||||
Average Receivables |
6.37 | 6.57 | — | 11.77 | |
Average Payables |
10.63 | 9.01 | 2.38 | 14.73 | |
Average Inventory |
— | — | — | 11.68 | |
Average Assets |
20.30 | 20.40 | 41.82 | 44.68 | |
Average Common Equity |
(1.28) | (1.03) | (6.83) | 7.32 |
Columns are period end dates